Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment. Here, we report the final overall survival results from this study based on an unplanned second interim analysis.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Jul 2016

Volume: 17

Issue: 7

Affiliations

[1 ] Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.

[2 ] Institut Gustave Roussy, Villejuif, France.

[3 ] Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London, UK.

[4 ] University of Texas, MD Anderson Cancer Center Hospital, Houston, TX, USA.

[5 ] Icon Cancer Care, Brisbane, Queensland, Australia.

[6 ] Cleveland Clinic Foundation, Cleveland, OH, USA.

[7 ] Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.

[8 ] Aarhus University Hospital, Aarhus, Denmark.

[9 ] Washington University in St Louis, St Louis, MO, USA.

[10 ] Helsinki University Central Hospital Cancer Center, Helsinki, Finland.

[11 ] Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

[12 ] Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.

[13 ] Medical University of Vienna, Vienna, Austria.

[14 ] Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah.

[15 ] San Camillo and Forlanini Hospitals, Rome, Italy.

[16 ] Beth Israel Deaconess Medical Center, Boston, MA, USA.

[17 ] Exelixis, South San Francisco, CA, USA.

[18 ] Texas Oncology-Baylor Sammons Cancer Center, Dallas, TX, USA.

[19 ] City of Hope National Medical Center, Duarte, CA, USA.

[20 ] Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Article

Publisher Item ID: S1470-2045(16)30107-3

DOI: 10.1016/S1470-2045(16)30107-3

PubMed ID: 27279544

SO-VID: 60d68af9-cdd8-4df2-9e60-37aa32b3e644

History

Data availability:

Comments

Comment on this article

scite_

Cited by 304

See all cited by